Last reviewed · How we verify

Pulmonary Arterial Hypertension (PAH) — Treatment Landscape & Competitive Intelligence

Pulmonary Arterial Hypertension (PAH) (Cardiovascular) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Cardiovascular 10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pulmonary Arterial Hypertension (PAH), deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Uptravi SELEXIPAG AstraZeneca Prostacyclin Receptor Agonist [EPC] Prostacyclin receptor 2015-01-01
Opsumit MACITENTAN AstraZeneca Endothelin Receptor Antagonist [EPC] Endothelin-1 receptor 2013-01-01
Adempas RIOCIGUAT Bayer Soluble Guanylate Cyclase Stimulator [EPC] Guanylate cyclase soluble subunit beta-1 2013-01-01
Letairis AMBRISENTAN Gilead Sciences Endothelin Receptor Antagonist [EPC] Endothelin-1 receptor 2007-01-01
Remodulin TREPROSTINIL United Therap Prostacycline Vasodilator [EPC] Prostacyclin receptor 2002-01-01
Tracleer BOSENTAN AstraZeneca Endothelin Receptor Antagonist Endothelin-1 receptor 2001-01-01
Viagra sildenafil Pfizer Inc. PDE5 inhibitor Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A, Multidrug resistance-associated protein 5 1998-03-27
Flolan EPOPROSTENOL AstraZeneca Prostacycline Vasodilator [EPC] Prostacyclin receptor 1995-01-01
prostacyclin prostacyclin United Therapeutics P2Y purinoceptor 12, Prostacyclin receptor, Prostaglandin E2 receptor EP1 subtype
Revatio Sildenafil Citrate Pfizer Inc. PDE5 inhibitor Phosphodiesterase type 5 (PDE5)

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. AstraZeneca · 4 drugs in Pulmonary Arterial Hypertension (PAH)
  2. Pfizer Inc. · 2 drugs in Pulmonary Arterial Hypertension (PAH)
  3. Gilead Sciences · 1 drug in Pulmonary Arterial Hypertension (PAH)
  4. Meshalkin Research Institute of Pathology of Circulation · 1 drug in Pulmonary Arterial Hypertension (PAH)
  5. Pfizer · 1 drug in Pulmonary Arterial Hypertension (PAH)
  6. Prim PD Dr Afshin Assadian · 1 drug in Pulmonary Arterial Hypertension (PAH)
  7. United Therap · 1 drug in Pulmonary Arterial Hypertension (PAH)
  8. United Therapeutics · 1 drug in Pulmonary Arterial Hypertension (PAH)
  9. · 1 drug in Pulmonary Arterial Hypertension (PAH)
  10. University of Colorado, Denver · 1 drug in Pulmonary Arterial Hypertension (PAH)
  11. Bayer · 1 drug in Pulmonary Arterial Hypertension (PAH)

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pulmonary Arterial Hypertension (PAH):

Cite this brief

Drug Landscape (2026). Pulmonary Arterial Hypertension (PAH) — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pulmonary-arterial-hypertension. Accessed 2026-05-16.

Related